Press release content from Business Wire. The AP news staff was not involved in its creation. Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients February 26, 2021 GMT WILMINGTON, Del.--(BUSINESS WIRE)--Feb 26, 2021-- Positive full results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab demonstrated a statistically significant and clinically meaningful 1 reduction in the annualized asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients. 2 The results were presented at the American Academy of Asthma Allergy & Immunology Virtual Annual Meeting. 2 Tezepelumab, a potential first-in-class medicine, when added to standard of care (SoC) achieved a 56% reduction (p 0.001) in AAER over 52 weeks in the overall patient population, compared to placebo when added to SoC. 2 SoC was medium- or high-dose inhaled corticosteroids (ICS) plus at least one additional controller medication with or without oral corticosteroids (OCS). 2